APA (7th ed.) Citation

Le Saux, O., Ardin, M., Berthet, J., Barrin, S., Bourhis, M., Cinier, J., . . . Ray-Coquard, I. (2024). Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma. Nature Communications, 15(1), . https://doi.org/10.1038/s41467-024-47000-5

Chicago Style (17th ed.) Citation

Le Saux, Olivia, et al. "Immunomic Longitudinal Profiling of the NeoPembrOv Trial Identifies Drivers of Immunoresistance in High-grade Ovarian Carcinoma." Nature Communications 15, no. 1 (2024). https://doi.org/10.1038/s41467-024-47000-5.

MLA (9th ed.) Citation

Le Saux, Olivia, et al. "Immunomic Longitudinal Profiling of the NeoPembrOv Trial Identifies Drivers of Immunoresistance in High-grade Ovarian Carcinoma." Nature Communications, vol. 15, no. 1, 2024, https://doi.org/10.1038/s41467-024-47000-5.